Xiao Su

发表

Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Hongyi Zhang, 2022, Cancer Immunology, Immunotherapy.

Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.

H. Kuerer, V. Valero, S. Krishnamurthy, 2015, Journal of the National Cancer Institute.

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Li Liu, 2022, British Journal of Cancer.

Expression of CD133 correlates with differentiation of human colon cancer cells.

Hong Zhang, Xiaojie Bian, B. Gu, 2010, Cancer biology & therapy.

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Y. Zhu, Le Xu, Jiejie Xu, 2022, British Journal of Cancer.

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome geneKDM6Amutation

Le Xu, Jiejie Xu, Yu Zhu, 2023, BMJ Oncology.

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

Le Xu, Jiejie Xu, Yu Zhu, 2024, British journal of cancer.

RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.

Yu Zhu, Weijuan Zhang, Zewei Wang, 2024, Journal of immunotherapy.

Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

Le Xu, Yu Zhu, Weijuan Zhang, 2024, Cancer science.

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma

Le Xu, Jiejie Xu, Yu Zhu, 2024, The Journal of pathology.

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Le Xu, Jiejie Xu, Yu Zhu, 2024, Cancer medicine.